CBPO - China Biologic Products Holdings, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
91.00
+0.69 (+0.76%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close90.31
Open90.72
Bid70.50 x 1000
Ask91.00 x 1800
Day's Range90.01 - 91.21
52 Week Range60.08 - 107.44
Volume119,301
Avg. Volume283,160
Market Cap3.546B
Beta (3Y Monthly)0.85
PE Ratio (TTM)25.58
EPS (TTM)3.56
Earnings DateAug 1, 2019 - Aug 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est93.01
  • China Biologic Products Inc (CBPO) Q1 2019 Earnings Call Transcript
    Motley Fool12 days ago

    China Biologic Products Inc (CBPO) Q1 2019 Earnings Call Transcript

    CBPO earnings call for the period ending March 31, 2019.

  • China Biologic Products (CBPO) Tops Q1 Earnings and Revenue Estimates
    Zacks15 days ago

    China Biologic Products (CBPO) Tops Q1 Earnings and Revenue Estimates

    China Biologic Products (CBPO) delivered earnings and revenue surprises of 12.12% and 8.61%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press15 days ago

    China Biologic Products: 1Q Earnings Snapshot

    The Beijing-based company said it had net income of 94 cents per share. Earnings, adjusted for non-recurring costs, were $1.11 per share. The biopharmaceutical company posted revenue of $129.8 million ...

  • PR Newswire15 days ago

    China Biologic Reports Financial Results for the First Quarter of 2019

    --1Q19 Total Sales Up 15.4% YoY in USD terms, or 22.3% YoY in RMB terms; Net Income Up 19.3% YoY to $37.7 Million ; Non-GAAP Adjusted Net Income Up 14.3% YoY in RMB terms -- BEIJING , May 10, 2019 /PRNewswire/ ...

  • Earnings Preview: China Biologic Products (CBPO) Q1 Earnings Expected to Decline
    Zacks22 days ago

    Earnings Preview: China Biologic Products (CBPO) Q1 Earnings Expected to Decline

    China Biologic Products (CBPO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • PR Newswire25 days ago

    China Biologic Products to Report First Quarter 2019 Financial Results

    BEIJING , April 30, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical ...

  • Is China Biologic Products Inc (CBPO) A Good Stock To Buy According To Hedge Funds?
    Insider Monkey28 days ago

    Is China Biologic Products Inc (CBPO) A Good Stock To Buy According To Hedge Funds?

    World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients' money after undertaking a rigorous examination of any potential stock. They are particularly successful in this regard when it comes to small-cap stocks, which their peerless research gives them a big information advantage on when it comes to judging their worth. […]

  • Analysts Estimate China Biologic Products (CBPO) to Report a Decline in Earnings: What to Look Out for
    Zacks29 days ago

    Analysts Estimate China Biologic Products (CBPO) to Report a Decline in Earnings: What to Look Out for

    China Biologic Products (CBPO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • New Strong Sell Stocks for April 9th
    Zacks2 months ago

    New Strong Sell Stocks for April 9th

    Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today.

  • Markit2 months ago

    See what the IHS Markit Score report has to say about China Biologic Products Holdings Inc.

    China Biologic Products Holdings Inc NASDAQ/NGS:CBPOView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is low for CBPO with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding CBPO are favorable, with net inflows of $241 million. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • New Strong Sell Stocks for March 22nd
    Zacks2 months ago

    New Strong Sell Stocks for March 22nd

    Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today

  • New Strong Sell Stocks for March 18th
    Zacks2 months ago

    New Strong Sell Stocks for March 18th

    Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today

  • China Biologic Products Inc (CBPO) Q4 2018 Earnings Conference Call Transcript
    Motley Fool3 months ago

    China Biologic Products Inc (CBPO) Q4 2018 Earnings Conference Call Transcript

    CBPO earnings call for the period ending December 31, 2018.

  • PR Newswire3 months ago

    China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2018

    -- 4Q18 Total Sales Up 27.5% YoY in USD terms, or 33.5% YoY in RMB terms; Net Income Up $59.4 Million YoY to $34.8 Million ; Non-GAAP Adjusted Net Income Up 23.9% YoY in RMB terms -- -- FY18 Total Sales ...

  • PR Newswire3 months ago

    China Biologic Products to Report Fourth Quarter and Fiscal Year 2018 Financial Results

    BEIJING , Feb. 25, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical ...

  • Dalton Investments’ Return, AUM, and Holdings
    Insider Monkey4 months ago

    Dalton Investments’ Return, AUM, and Holdings

    Exactly 30 years ago, Steve Persky, James Rosenwald, and Gifford Combs joined together to form Dalton Investments, a Santa Monica – based hedge fund. What made these three businessmen join together as a team was a serious investment experience in Asia and a vision of an investment management firm with a main focus on the […]

  • PR Newswire5 months ago

    China Biologic Reiterates Full Year 2018 Financial Forecast

    BEIJING, Jan. 7, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO)("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today reiterated its previously revised full year 2018 forecast. Full year 2018 non-GAAP adjusted income from operations is expected to increase in the range of 0% to 2% in RMB terms and non-GAAP adjusted net income is expected to decrease by 2% to 4% in RMB terms over full year 2017 financial results. Excluding TianXinFu, full year 2018 non-GAAP adjusted income from operations is expected to decrease by 16% to 18% in RMB terms and non-GAAP adjusted net income to decrease by 19% to 21% in RMB terms over full year 2017 financial results.